Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 2 (2005), Issue 8 (August)

1. Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients.
   Pharmacoepidemiol Drug Saf, 14(8): 545-53. [Abstract] [Full-text]
2. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
   Clin Cancer Res, 11(15): 5631-8. [Abstract] [Full-text]
3. Killing time for cancer cells.
   Nat Rev Cancer, 5(7): 573-80. [Abstract] [Full-text]
4. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
   Leukemia, 19(7): 1198-206. [Abstract] [Full-text]
5. Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
   Leukemia, 19(7): 1184-91. [Abstract] [Full-text]
6. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.
   Proc Natl Acad Sci U S A, 102(31): 11011-6. [Abstract] [Full-text]
7. Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a.
   Blood, 106(4): 1355-61. [Abstract] [Full-text]
8. Emerging drugs for adult acute lymphoblastic leukaemia.
   Expert Opin Emerg Drugs, 10(3): 591-617. [Abstract] [Full-text]
9. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
   Cancer, 104(4): 777-80. [Abstract] [Full-text]
10. Autocrine signaling of platelet-derived growth factor regulates disabled-2 expression during megakaryocytic differentiation of K562 cells.
    FEBS Lett, 579(20): 4395-401. [Abstract] [Full-text]
11. Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma.
    Oncology, 68(2): 269-75. [Abstract] [Full-text]
12. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
    J Clin Oncol, 23(23): 5357-64. [Abstract] [Full-text]
13. T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
    Mol Cancer Ther, 4(8): 1167-74. [Abstract] [Full-text]
14. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
    Eur J Cancer, 41(12): 1751-7. [Abstract] [Full-text]
15. Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.
    Br J Haematol, 130(4): 558-60. [Abstract] [Full-text]
16. Philadelphia positive acute lymphoblastic leukaemia of childhood.
    Br J Haematol, 130(4): 489-500. [Abstract] [Full-text]
17. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.
    Bone Marrow Transplant, 36(5): 417-24. [Abstract] [Full-text]
18. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    BJU Int, 96(4): 640-6. [Abstract] [Full-text]
19. Philadelphia-chromosome positive thrombocythemia in a child.
    Eur J Haematol, 75(3): 262-3. [Abstract] [Full-text]
20. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
    J Clin Oncol, 23(24): 5795-804. [Abstract] [Full-text]
21. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Leuk Lymphoma, 46(9): 1375-7. [Abstract] [Full-text]
22. Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis.
    Leuk Res, 29(10): 1227-32. [Abstract] [Full-text]
23. Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.
    J Biol Chem, 280(34): 30254-62. [Abstract] [Full-text]
24. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leukemia, 19(9): 1509-16. [Abstract] [Full-text]
25. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
    Leukemia, 19(9): 1579-89. [Abstract] [Full-text]
26. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Leukemia, 19(9): 1536-42. [Abstract] [Full-text]
27. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
    Leukemia, 19(9): 1590-6. [Abstract] [Full-text]
28. Induction of centrosome and chromosome aberrations by imatinib in vitro.
    Leukemia, 19(9): 1573-8. [Abstract] [Full-text]
29. Antitumor activity of imatinib mesylate in neuroblastoma xenografts.
    Cancer Lett, 228(1): 211-9. [Abstract] [Full-text]
30. The role of surgery in the management of gastrointestinal stromal tumors (GISTs) in the era of imatinib mesylate effectiveness.
    Surg Oncol, 14(2): 75-84. [Abstract] [Full-text]
31. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib.
    Int J Cancer, 117(2): 316-25. [Abstract] [Full-text]
32. Does early stem-cell transplantation have a role in chronic myeloid leukaemia? For the proposal.
    Lancet Oncol, 6(9): 721-2. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.